December 1, 2020, is #GivingTuesday! Will you help #EndALS by fundraising or making a direct donation to ALS TDI? Your support fuels our research!

 

Riluzole

Riluzole may protect motor nerves from further deterioration by reducing glutamate levels in the brain and spinal cord by blocking its release from nerve terminals.

Status

Type: Small Molecule
Stage: FDA-Approved
Status: FDA-Approved

TDI Says:

Although it only has modest effects on disease progression, riluzole is the only FDA-approved drug for ALS.

Learn More

  • Postcard from Australia

    Neuroscience Research Australia’s Steve Vucic PhD discusses emerging combination treatment strategies including riluzole that may reduce hyperexcitability, a potential early step in the disease.

Published Results

Comment on this Topic

(All comments are moderated before they appear here.)